Navigation Links
Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients.  Over the past 6 years, UCB has awarded more than 200 scholarships, totaling over $1 million, to people whose lives have been directly affected by epilepsy, including those with epilepsy, their caregivers and family members.  Epilepsy is a common neurological condition that can affect anyone at anytime.  In the United States, 1 in 100 people are living with epilepsy.

"It is inspiring to see that year after year UCB recognizes the dreams of people affected by epilepsy and supports these individuals in accomplishing their academic aspirations," said Brien Smith, MD, Henry Ford Hospital, Neurology.

This year, 40 recipients were selected from a pool of nearly 800 applicants. UCB awarded 30 scholarships to people living with epilepsy and 10 scholarships to family members or caregivers of someone living with epilepsy.  Each recipient will receive a scholarship of $5,000 for tuition at colleges, graduate schools and technical schools across the country.  Applicants were considered based on their application, personal essay, letters of recommendation and their determination to live beyond the boundaries of epilepsy.

This year's recipients will be honored on the UCB Family Epilepsy Scholarship Facebook page.  To see photos and quotes from the 2010 recipients, read updates from past scholarship recipients and learn more about the UCB Family Epilepsy Scholarship Program™, please go to Facebook.com/UCBEpilepsyScholarship.  

2010 Scholarship Recipients and Their Selected Learning Institution:Emerald Allen

Concordia Lutheran UniversityKamell Ean Alston

West Chester UniversityCourtney Barringtine

Howard UniversityBeth Barton

Roosevelt UniversityAshley Breedlove

Midwestern State UniversityTravis Brown

Bowling Green Technical CollegeDalton Burghardt

California State University ChicoMadeleine Clifton

James Madison UniversityErin Cline

Glen Oaks Community CollegeDanielle DellaVella

Whitworth UniversityKristen Emerson

University of ConnecticutKaren Escobedo

University of California RiversideTanya Evans

Youngstown State UniversitySamuel Fazioli

Northeastern UniversityClaire Fons

University of Wisconsin MilwaukeeDai Quan Garner

Wesley CollegeDeborah Gunn

National UniversityCarrie Harpole

Henderson Community CollegePaul Anthony Henderson Jr.

University of South CarolinaAndrew Hibbitt

Florida Gulf Coast UniversityEmma Himpelmann

Kendall CollegeAaron Hoover

University of Southern IndianaEliza Jacobs-Brichford

Ithaca CollegeKatherine Japp

University of Texas, BrownsvilleAmanda Johnson

University of Pittsburgh Shelley Kays

Community College of MorrisTim Kelly

Central Michigan UniversityHannah Nicole Lawrence

Hinds Community CollegeMaureen Mahon

St. Louis UniversityEmmanuel Marrero

University of ToledoAmanda Mills

Goldey-Beacom CollegeLaKeisha Parnell

Atlanta Christian CollegeAshlin Phelps

Whitworth UniversityChristian Profitt

Midway CollegeAllison Rapsas

American Musical and Dramatic Academy Patrick Sheeran

George Mason UniversityKaitlyn Votel

St. Catherine UniversityLauren Wilson

Seattle UniversitySelena Winter

Adelphi UniversityAbout Epilepsy Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and three million people in the U.S.—making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Roughly 20-30 percent of people living with epilepsy have either uncontrolled seizures or significant side effects secondary to medication. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit www.EpilepsyAdvocate.com.

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

The UCB Family Epilepsy Scholarship Program™ is a trademark of the UCB group of companies.

Further InformationAndrea LevinSenior Manager, Communications & PR, CNS, UCB, Inc.T 770.970.8352M 404.483.7329Andrea.Levin@ucb.comLaura FinleyCooney/Waters GroupT 212.886.2258LFinley@cooneywaters.com
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
3. Cypin Production Announces Launch of U.S./China BioPharma Conference:
4. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
5. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
7. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
8. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
9. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
11. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
Breaking Medicine News(10 mins):